Prof. Katherine Tkaczuk

University of Maryland, USA

Email: [email protected]

Qualifications

1984 M.Sc., Wroclaw Medical Academy, Poland

Publications (selected)

1. Tkaczuk, K.H., Hu, K., Rosenblatt, P.Y. and Serrero, G. Abstract PS5-09-03: Prospective longitudinal study of circulating serum progranulin (PGRN/GP88) levels and its association with tumor response to therapies in patients with metastatic breast cancer (MBC). Clinical Cancer Research, 2026.  
2. Knutson, K., Abu-Fares, H., Keating, P. and Sharma, P. A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research, 2025.  
3. Weight, R.M., Falchook, G.S., Julian, R.A. and Giacalone, M.J. 615 Phase 1 study of intratumoral VAX014 with dose expansion in combination with pembrolizumab or nivolumab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 2025.  
4. Kleckner, A.S., Mocci, E., Clingan, C.L. and Dorsey, S.G. Transcriptomic Profiles and Functional Correlates of Cancer‐Related Fatigue: A Cross‐Sectional Study in Women Undergoing Cancer Treatment. European Journal of Cancer Care, 2025.  
5. Tkaczuk, K.H., Rosenblatt, P., Scilla, K.A. and Serrero, G. Phase 1 first-in-human clinical trial of AG01, a recombinant monoclonal antibody to progranulin/glycoprotein 88 (PGRN/GP88), to determine the safety, tolerability, pharmacokinetics, and preliminary anti-tumor response in subjects with advanced solid tumor malignancies. Journal of Clinical Oncology, 2025.  
6. Derakhshandeh, R., Zhu, Y., Li, J. and Webb, T.J. Identification of Functional Immune Biomarkers in Breast Cancer Patients. International Journal of Molecular Sciences, 2024.  
7. Buchbinder, E.I., Weight, R.M., Chalasani, P. and Giacalone, M.J. 667 Phase 1 study of intratumoral administration of VAX014 in subjects with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 2024.  
8. Shi, C., Bopp, T., Lo, H.-W. and Lin, J. Bazedoxifene as a Potential Cancer Therapeutic Agent Targeting IL-6/GP130 Signaling. Current Oncology, 2024.  
9. Tkaczuk, K.H., Rosenblatt, P., Mehra, R. and Serrero, G. Abstract PO5-18-06: On-going phase 1A clinical trial of A01, a chimerized monoclonal antibody to Progranulin/Glycoprotein 88 (GP88) in patients with advanced malignancy. Cancer Research, 2024.  
10. Feigenberg, S.J., Bentzen, S.M., Milburn, M. and Nichols, E.M. A prospective trial of single-fraction radiation to the tumor bed with a novel breast-specific stereotactic radiotherapy device: The GammaPod. Advances in Radiation Oncology, 2024.  
11. Fulton, A.M. and Tkaczuk, K.H. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer. Chapter, 2023.  
12. Wang, H., Agarwal, P., Jiang, B. and He, X. Bioinspired One Cell Culture Isolates Highly Tumorigenic and Metastatic Cancer Stem Cells Capable of Multilineage Differentiation. Advanced Science, 2023.  
13. Tkaczuk, K.H., Rosenblatt, P., Mehra, R. and Serrero, G. Abstract CT240: On-going phase 1A clinical trial for AG01 an first-in-class anti-progranulin (GP88) monoclonal antibody in patients with advanced malignancies. Cancer Research, 2023.  
14. Serrero, G., Rosenblatt, P., Tait, N. and Tkaczuk, K.H. Abstract OT3-16-01: On-going prospective study to measure serum progranulin/GP88 levels in metastatic breast cancer patients in association with disease status. Cancer Research, 2023.  
15. Tkaczuk, K.H., Rosenblatt, P., Mehra, R. and Serrero, G. Abstract OT3-13-01: First in Human Study of AG01 a chimerized monoclonal antibody to Progranulin/Glycoprotein 88 (GP88). Cancer Research, 2023.  
16. Dillon, P., Basho, R., Han, H.S. and Boni, V. Abstract OT1-03-06: Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress). Cancer Research, 2023.  
17. Ou, W., Stewart, S., White, A. and He, X. In-situ cryo-immune engineering of tumor microenvironment with cold-responsive nanotechnology for cancer immunotherapy. Nature Communications, 2023.  
18. Kwizera, E.A., Ou, W., Lee, S. and He, X. Correction to Greatly Enhanced CTC Culture Enabled by Capturing CTC Heterogeneity Using a PEGylated PDMS-Titanium-Gold Electromicrofluidic Device with Glutathione-Controlled Gentle Cell Release. ACS Nano, 2022.  
19. Kwizera, E.A., Ou, W., Lee, S. and He, X. Greatly Enhanced CTC Culture Enabled by Capturing CTC Heterogeneity Using a PEGylated PDMS–Titanium–Gold Electromicrofluidic Device with Glutathione-Controlled Gentle Cell Release. ACS Nano, 2022.  
20. Dang, C., Tolaney, S.M., Riaz, F. and Rugo, H. Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic. Journal of Clinical Oncology, 2022.  
21. Xu, J., Liu, Y., Liu, S. and He, X. Metformin Bicarbonate-Mediated Efficient RNAi for Precise Targeting of TP53 Deficiency in Colon and Rectal Cancers. Nano Today, 2022.  
22. Tkaczuk, K.H., Rosenbatt, P., Sulkowski, S. and Serrero, G. Abstract OT1-05-01: Glycoprotein 88 (GP-88) serum levels as a marker of response to therapy in patients with metastatic breast cancer. Cancer Research, 2022.  
23. Hatem, S., Hargis, J., Elias, A. and Hamilton, E. Abstract P5-16-02: Updated efficacy, safety and translational data from MARIO-3, a phase II open-label study evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC). Cancer Research, 2022.  
24. Tsai, M., Han, H.S., Montero, A.J. and Burris, H.A. 259P Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer. Annals of Oncology, 2021.

Personal Details

WoS Researcher ID: HOF-3866-2023

https://orcid.org/0000-0002-5978-5215

https://www.umms.org/find-a-doctor/profiles/dr-katherine-h-tkaczuk-md-1225079601

https://www.sciencedirect.com/author/55939361300/katherine-h-rak-tkaczuk

https://www.researchgate.net/profile/Katherine-Tkaczuk